ObjectiveThe aim of the study was to investigate the correlations between pathological grade, serum prostate-specific antigen (PSA)
and bone scintigraphy in the diagnosis of metastasis diseases for prostate cancers, and to explore the characteristics of
bone metastases for prostate cancer.
MethodsSeventy-seven newly diagnosed prostate cancers were reviewed in the study. All the cases underwent bone scintigraphy, total
serum PSA measurement by luminescent immunoassay before operation and were classified according to post-operative pathology
diagnosis. We analyzed the correlations of the bone metastasis incidences and different pathological grades or different PSA
ResultsBone scans were indicative of metastases in 33 cases (42.86%). Significantly higher incidence of bone metastasis was observed
in patients with poorly differentiated prostate cancer compared with patients with well (gC2 = 10.880, P = 0.001 < 0.05) and moderately (gC2 = 6.166, P = 0.013 < 0.05) differentiated prostate cancers. No significant difference between the well differentiated and moderately
differentiated prostate cancers was found (gC2 = 0.612, P = 0.434 > 0.05). The serum PSA concentration had significant correlation with the incidence of bone metastasis. In 26 patients
with PSA < 20 ng/mL, 5 cases (19.23%) had bone metastasis while 28 of 51 cases (54.90%) with PSA > 20 ng/mL had bone metastasis.
The serum PSA concentration had positive correlation with pathological grades of prostate cancer (r = 0.535, P = 0.01).
ConclusionBone scintigraphy plays a great role in the diagnosis of bone metastasis for prostate cancer patients currently. The poorly
differentiated prostate cancer and PSA > 20 ng/mL most likely suggested the possibility of bone metastasis.
The Chinese-German Journal of Clinical Oncology 01/2009; 8(12):702-704. DOI:10.1007/s10330-009-0150-3